A Dose Optimisation Study of ASLAN003 in Acute Myeloid Leukemia
Status:
Completed
Trial end date:
2019-12-13
Target enrollment:
Participant gender:
Summary
ASLAN003-003 is a multi-center, Phase IIA study to evalute the efficacy of ASLAN003 in AML
patients who are ineligible for standard treatment with an expansion cohort in
relapsed/refractory patients, and to determine the appropriate dose of ASLAN003 in
combination with azacitidine in older (more than or equal to 60 years) AML patients who have
exhausted any approved and available treatment options.